Trial Shows Benefit of 'BRCA-Targeting' Drug in Prostate Cancer

“Men with prostate cancer benefit from treatment with the pioneering drug olaparib – the first cancer drug to target inherited mutations – according to the results of a major trial presented today (Tuesday).

“Olaparib was licensed in December for women with ovarian cancer and inherited BRCA mutations, but the new research suggests it could also benefit men with genomic faults within their tumours.

“Researchers told the American Association of Cancer Research (AACR) conference in Philadelphia that up to 30 per cent of men with advanced prostate cancer had tumours with defects in repairing DNA – and these responded particularly well to olaparib.

“The men most likely to benefit could be identified by genetic testing to look for mutations in genes responsible for DNA repair – including the BRCA genes and the gene ATM.”


Metformin Inhibits Growth and Enhances Radiation Response of Non-Small Cell Lung Cancer (NSCLC) Through ATM and AMPK

“We examined the potential of metformin (MET) to enhance non-small cell lung cancer (NSCLC) responses to ionising radiation (IR)…”